Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy

Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy

Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determinat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kawa Mohemed, Smita Scholtz, Volker Rudolph, Jan-Christian Reil, Max Potratz, Cédric Coppée, Vasco Sequeira, Werner Scholtz
Format: Article
Language:English
Published: BMJ Publishing Group 2025-03-01
Series:Open Heart
Online Access:https://openheart.bmj.com/content/12/1/e003192.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items